Sagility Limited
(Formerly Sagility India Limited, earlier Sagility India Private Limited)
Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur 
Road, Bommanahalli, Bengaluru – 560068, Karnataka, India
Corporate Identification Number: L72900KA2021PLC150054
Tel. No.: 080-71251500, E-mail: investorservices@sagility.com, Website: www.sagilityhealth.com
Date: October 29, 2025
To, 
The Manager 
Listing Department 
National Stock Exchange of India Limited (NSE) 
Exchange Plaza, 5th Floor 
Plot No. C/1, G-Block 
Bandra-Kurla Complex 
Bandra (E), Mumbai - 400 051 
Symbol: SAGILITY
To,
The Manager 
Listing Department 
BSE Limited (BSE) 
Phiroze Jeejeebhoy Towers 
Dalal Street Mumbai - 400 001 
Scrip Code:544282
Dear Sir/Ma’am, 
Subject: Submission of Investor Presentation to be made to investors on October 29, 2025,
pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and 
Disclosure Requirements) Regulations, 2015
In continuation of our letter dated October 17, 2025, please find enclosed the presentation to be made to 
investors on the financial results of Sagility Limited for the quarter and half-year ended September 30, 
2025, during the meeting scheduled today, i.e., Wednesday, October 29, 2025, at 7:30 p.m. (IST).
The details are also being made available on the Company’s website https://sagilityhealth.com/
This is for your kind information and record.
Thanking You, 
For Sagility Limited 
(formerly Sagility India Limited, Sagility India Private Limited)
Satishkumar Sakharayapattana Seetharamaiah   
Company Secretary & Compliance Officer   
M. No: A16008
Encl: a/a

Investor Deck – Q2 FY26
October 29, 2025

Safe Harbour
Certain statements in this release concerning Sagility’ future growth prospects may be seen as forwardlooking statements, which involve a number of risks and uncertainties that could cause the actuals to differ 
materially from such statements. Sagility does not undertake to update any such statement that may have 
been made from time to time by or on behalf of the company..
2

Performance Highlights
₹ 16,585 
million
Organic Y-o-Y 
growth
16.0%
11.1 % at Constant 
Currency
Y-o-Y growth
25.2%
20..0% at Constant 
Currency
₹ 4,352 
million
Margin %
26.2%
Y-o-Y growth 
25.6%
₹ 3,010 
million
Margin %
18.1%
Y-o-Y growth 
84.0%
₹ 31,974 
million
Organic Y-o-Y 
growth
16.9%
13.2 % at Constant 
Currency
Y-o-Y growth
25.5%
21..4% at Constant 
Currency
₹ 8,039 
million
Margin %
25.1%
Y-o-Y growth 
26.0%
₹ 5,007 
million
Margin %
15.7%
Y-o-Y growth 
62.4%
► 16.0% Y-o-Y organic growth in Q2 FY26 driven by expansion from 
existing clients, while new wins are expected to further strengthen 
momentum in H2
► $34 M (potential steady state ACV) of new business & expansion 
won in Q2 FY26
► Expansion and new SOWs from 24 existing clients in Q2 FY26
► 5 new clients onboarded in Q2 (total 9 in H1 FY26)
► 2 new SOWs from cross-sell to Broadpath clients in Q2 (3 in H1)
► Strong client engagement continues, with deal constructs evolving 
beyond traditional service delivery models. Sharper emphasis on 
transformation, consulting-led value creation, and measurable cost 
take-out initiatives.
Q2 FY26 summary H1 FY26 summary
Headcount
44,185
Clinicians & 
Technology heads 
3400+
► Great Place to Work-Certified in India in Sept 2025
► Winner of the Asia CEO Awards 2025 – “Service Excellence Company of the Year” for 
Sagility Philippines
Interim dividend of ₹0.05 per share

KPIs
4
Q2 FY26 Q1 FY26 Q2 FY25 YoY% H1 FY26 H1 FY25 YoY%
Revenue from Operation (in INR Million) 16,585 15,389 13,250 25.2% 31,974 25,484 25.5%
Revenue by Vertical Split
By Payer % 88.5% 88.4% 89.2% 88.4% 89.2%
By Provider % 11.5% 11.6% 10.8% 11.6% 10.8%
Growth in revenue from operation (%) 25.2% 25.8% 21.1% 25.5% 15.3%
Adjusted EBITDA (in INR Million) 4,352 3,687 3,465 25.6% 8,039 6,381 26.0%
Adjusted EBITDA % 26.2% 24.0% 26.1% 25.1% 25.0%
Adjusted PAT (in INR Million) 3,010 1,997 1,636 84.0% 5,007 3,083 62.4%
Adjusted PAT % 18.1% 13.0% 12.3% 15.7% 12.1%
Total Number of Employees 44,185 39,917 38,830 15.1% 44,185 38,830 15.1%
Voluntary attrition rate* (%) 26.3% 27.6% 25.8% 26.3% 26.7%
Note: 
Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis

Annual KPIs
5
H1 FY26 FY25 FY24 FY23
Number of Client groups*
Active 82 75 44 35
Number of new client addition (Gross) 9 38 13 7
Delivery sites
Number of delivery sites 34 33 30 27
New site addition (Gross) 3 10 4 2
TTM Sept 25 FY25 FY24 FY23
Client groups contribution to revenues
Top 3 Client % 63.1% 66.2% 68.3% 72.4%
Top 5 Client % 74.4% 77.9% 79.2% 80.6%
Top 10 Client % 87.6% 90.5% 91.4% 90.7%
Number of Million-dollar client groups
Number of clients contributing more than US$20 million 8 7 5 4
Number of clients contributing to US$5 - US$20 million 6 6 7 7
Number of clients contributing to US$1 - US$5 million 17 12 12 12
Number of clients contributing less than US$1 million 51 50 20 12
* Client groups comprise client entities together with their affiliates. 

Recent Market Updates
6
Market Changes Impact on Payer/ Provider Likely Impact on Sagility
Marketplace Integrity and Affordability 
Final Rule
► Payers must upgrade eligibility, enrollment, and 
compliance systems to meet stricter verification 
and reporting rules. Premium inflows to ACA 
focused payers likely to reduce. 
► Providers may face shifts in patient coverage, 
requiring tighter eligibility checks and revenuecycle vigilance
► Sagility is well positioned to support Payers in 
increased demand for automation-led Eligibility & 
enrolment validation.
HIRE Act 2025 ► 25% Excise tax on Outsourcing payments to 
foreign entities for services to US consumers. The 
bill has not yet passed the Senate or the House
► Margin compression of payers and providers 
► Payers and providers are expected to 
increasingly adopt technology-driven solutions to 
optimize costs.
► Even with proposed taxes, offshoring would 
remain more cost-effective than onshore.
Normalization of tariffs as a long-term 
policy measure
► Tariff driven increase in cost of imported medical 
equipment & Pharmaceuticals. Providers more 
exposed to Tariff risks than payers. 
► No tangible impact 
H- 1B policy ► Sagility does not rely on the H-1B program. 
► Over 99% of Sagility employees in the US are 
citizens or green card holders

Larger and more complex deal constructs
Transform in place
For a large national player, traditional levers 
like offshoring and automation has matured 
with diminishing returns. They wanted to 
unlock further cost savings through nextgeneration levers.
Sagility has created an AI-driven 
transform-in-place solution, which 
combined inputs from operations analytics, 
process engineering, AI/ML & GenAI to 
deliver an additional 20+% savings. 
Transform and elevate Engagement
A large regional payer wanted to achieve substantial 
cost takeout and elevate Member & Provider 
engagement experience, using Sagility’s cloudbased engagement services and GenAI.
Revenue Growth through 
bundled technology and services
A leading national payer providing B2B services 
(provider Network & claims repricing) to Health Benefit 
companies and other Health plans was looking to 
grow revenues by providing new services like 
provider payments and engagement.
Sagility designed a shared-services model along 
with a technology partner who will provide data 
aggregation services and integration with Sagility’s
CRM to enable operational services like Provider 
Payments and engagement.
Commercial construct in such models is 
“per-member-per-month (PMPM)” which 
will de-risk the payer vs traditional billing 
models like Transaction Rate or FTE rate. 
Savings delivered over committed 
reduction will have “Gain-Share”
Per-member-per-month (PMPM) model which 
covers both platform and operational expenses, 
delivering cost savings and reducing cost volatility for 
clients.
Sagility has proposed a GenAI-powered, cloud-based 
engagement solution to achieve 25-40% savings, 
across Members, Brokers and Provider interactions. The 
savings are from GenAI enabled transaction 
containment (self-service) and productivity 
improvement (Agent-Assist). 
Commitment on savings 
AI Agents to process transactions at a fraction of 
cost of transaction processed by humans.

Case Studies & White Papers Solution Videos Events & Expert Talks
One Big Beautiful Bill Act
Case Studies 
AI, RPA Improves Dental Appeals, Boosting Efficiency by 30%, Accuracy by 50%
AI, RPA Improves
Dental Appeals, Boosting 
Efficiency by 30%,
Accuracy by 50%
Agile Claims Migration to Facets Platform Saves $11M
Agile Claims 
Migration to Facets 
Platform Saves $11M
Corrected Claims RPA Saves Leading Blues Plan $1M
Corrected Claims RPA 
Saves Leading Blues 
Plan $1M
Claims Automation Saves $1.5M for Leading Payer
Claims Automation 
Saves $1.5M for Leading 
Payer
AHIP Webinar – October
Featuring insights and 
deployed examples of 
Sagi360 
Availity + Sagility
Co-marketed solution 
to be featured
AHIP Webinar –
September
Highest registration 
AHIP has had in 2025
AI-enabled Virtual Agent
Nurse Assist
Sagility Thought Leadership
What’s New & What’s Next for 2025

Financial Highlights

Financial Highlights
10
Q2 FY26 H1 FY26
₹ 16,585 
million
Organic Y-o-Y 
growth
16.0%
11.1 % at Constant 
Currency
Y-o-Y growth
25.2%
20.0 % at Constant 
Currency
₹ 4,352 
million
Margin %
26.2%
Y-o-Y 
growth %
25.6%
₹ 3,010 
million
Margin %
18.1%
Y-o-Y 
growth %
84.0%
₹ 31,974
million
Organic Y-o-Y 
growth
16.9%
13.2 % at Constant 
Currency
Y-o-Y growth
25.5%
21.4 % at Constant 
Currency
₹ 8,039
million
Margin %
25.1%
Y-o-Y 
growth %
26.0%
₹ 5,007 
million
Margin %
15.7%
Y-o-Y 
growth %
62.4%
₹ 5,585 
million
Conversion %
67.3%
DSO
78 days
₹ 2,374 
million
Conversion %
50.2%
DSO
78 days
25%+ growth on Revenue & Adjusted EBITDA. DSO of 78 days includes unbilled Revenues 

Quarterly Seasonality
36.5 36.6 35.0 35.9
38.4 39.6 39.4
Headcount 
(‘000) 39.9
38.4
44.2
11
June 23 to 
Sep 24
June 24 to 
Sep 25
₹10,941
₹12,602 ₹12,832 ₹12,233
₹13,250
22.6% 23.0% 24.5% 23.8% 26.1%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
45.0%
50.0%
 -
 2,000
 4,000
 6,000
 8,000
 10,000
 12,000
 14,000
 16,000
 18,000
Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25
Revenue INR M Adjusted EBITDA %
13,250 
14,531 
15,685 15,389 
16,585 
26.1% 28.4% 26.6% 24.0% 26.2%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
 4,000
 6,000
 8,000
 10,000
 12,000
 14,000
 16,000
 18,000
 20,000
 22,000
Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26
Revenue INR M Adjusted EBITDA %
Headcount 
(‘000)
BroadPath
Revenue ($M) $131.9 $150.8 $154.4 $146.6 $157.9
Revenue ($M) $157.9 $171.9 $181.8 $180.4 $189.4
Our Revenues exhibit seasonality. Growth in Q3 is driven by open-enrollment ramps and member acquisition (BroadPath)

Long Term Financial performance snapshot
Revenue 
(INR Million) 
FY25 YoY% TTM Sep YoY%
17.2% 22.1%
Adjusted EBITDA * 
(INR Million)
FY25 YoY% TTM Sep YoY%
28.4% 31.5%
Adjusted PAT
(INR Million)
FY25 YoY% TTM Sep YoY%
37.5% 59.2%
Revenue ($M) 
FY25 YoY% TTM Sep YoY%
14.9% 18.7%
Adjusted EBITDA* 
($M)
FY25 YoY% TTM Sep YoY%
25.9% 27.9%
Adjusted PAT
($M)
FY25 YoY% TTM Sep YoY%
34.8% 54.0%
12
*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
₹47,536
₹55,699 ₹50,917
₹62,190
FY24 FY25 TTM Sep'24 TTM Sep 25
₹11,436
₹14,685
₹12,425
₹16,343
FY24 FY25 TTM Sep'24 TTM Sep 25
$572.9
$658.3 $609.8
$723.6
FY24 FY25 TTM Sep'24 TTM Sep 25
$137.8
$173.6
$148.8
$190.3
FY24 FY25 TTM Sep'24 TTM Sep 25
₹5,896
₹8,107
₹6,301
₹10,031
FY24 FY25 TTM Sep'24 TTM Sep 25
$71.1
$95.8
$75.9
$116.9
FY24 FY25 TTM Sep'24 TTM Sep 25
Consistent Revenue Growth. Expansion in EBITDA margins & reduction in interest and amortization expense driving higher PAT growth 

Other Financial Indicators
Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares
Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities)
Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent including investment in Mutual Fund and Deposits . Borrowing doesn’t include accrued interest
13
87.2% 89.7%
70.8% 67.3%
80.5%
57.6%
FY24 FY25 YTD Sep 25
Cash Conversion (%)
OCF % FCF %
₹21,678
₹10,433
₹6,199
1.9x
0.71x
0.38x
 -
 0.50
 1.00
 1.50
 2.00
 2.50
₹0
₹5,000
₹10,000
₹15,000
₹20,000
₹25,000
FY24 FY25 TTM Sep 25
Net Debt
Net Debt (in INR Million) Net Debt to Adjusted EBITDA
1.38 
1.76 
2.15 
FY24 FY25 TTM Sep 25
Adjusted EPS (in INR)
47.0%
54.9% 54.8%
FY24 FY25 TTM Sep 25
Adjusted ROCE %
Cash conversion in H1 FY26 @ 57.6% driven by higher Non-cash (unrealized) forex Gains & advance tax payments in Q2

Q2 FY26 Consolidated Profit and Loss
14
Particulars Q2 FY26 Q1 FY26 Q2 FY25 YoY% QoQ% H1 26 H1 25 YoY%
Revenue from Operation 16,585 15,389 13,250 25.2% 7.8% 31,974 25,484 25.5%
Employee benefits expense* 10,070 9,646 7,912 19,715 15,439
Other expenses^ 2,163 2,056 1,874 4,220 3,664
Adjusted EBITDA** 4,352 3,687 3,465 25.6% 18.0% 8,039 6,381 26.0%
Adjusted EBITDA % 26.2% 24.0% 26.1% 25.1% 25.0%
Adjustments:
M&A Earnouts 127 155 120 283 244
SAR (stock appreciation right) – Non 
Cash 73 71 93 145 945
Other Income^^ 65 50 153 115 189
Forex Gain / (Loss) 516 49 -241 566 -32
Reported EBITDA 4,733 3,560 3,165 49.6% 33.0% 8,293 5,349 55.0%
Finance costs 250 274 297 524 671
Depreciation and amortisation 1,215 1,182 1,264 2,397 2,363
Profit Before Tax 3,268 2,104 1,604 103.7% 55.3% 5,372 2,314 132.1%
Tax Expenses 760 618 431 1,378 918
Reported Profit After Tax 2,508 1,486 1,173 113.8% 68.8% 3,994 1,396 186.0%
EPS 0.54 0.32 0.25 113.8% 68.8% 0.85 0.31 178.3%
Adjusted PAT 3,010 1,997 1,636 84.0% 50.7% 5,007 3,083 62.4%
Adjusted PAT % 18.1% 13.0% 12.3% 15.7% 12.1%
Adjusted EPS (Rs) 0.64 0.43 0.35 84.0% 50.7% 1.07 0.68 58.0%
*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), 
^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately.
** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).
Amt in INR M

Adjustments on EBITDA and PAT
Adj EBITDA Bridge: Q2 FY26
Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax
Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible)
Adj C - Amortization of intangible assets that got created due to carveout of healthcare business from HGS
Adj PAT Bridge: Q2 FY26
INR Million
INR Million
15
₹4,733 ₹127 ₹73
-₹582
₹4,352
Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA
₹2,508 ₹93 ₹73
₹336 ₹3,010
Reported PAT Adj A Adj B Adj C Adjusted PAT
₹8,293 ₹283 ₹145
-₹681
₹8,039
Reported EBITDA Adj A Adj B Other Income/Fx gain Adjusted EBITDA
Adj EBITDA Bridge: H1 FY26
INR Million
Adj PAT Bridge: H1 FY26
INR Million
₹3,994 ₹206 ₹145
₹662 ₹5,007
Reported PAT Adj A Adj B Adj C Adjusted PAT
Reported 
EBITDA Adj A Adj B Other income/ 
FX gain Adjusted EBITDA Reported 
EBITDA Adj A Adj B Other income/ 
FX gain Adjusted EBITDA

Go Forward Positions
• Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS
• Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33 
16
Particulars FY25 FY26 FY27 FY28 FY29 FY30
Closing Debt position 8,020 5,670
Debt Repayment 2,490 2,350 5,670
Interest Payment 751 535 285
Share based Payment awards 1,134 255 151 80 41
Earnouts Cost - DCI / Birch/ BroadPath 571 503 5
Intangibles Amortisation (A) 1,400 1,443 1,456 1,456 1,456 1,456
Intangibles Amortisation (B) 188 387 380 366 291 247
Amt in INR M
Debt to be fully repaid by FY27.

Balance Sheet - 30th September 25
17
Particulars Sep 25 Mar 25
Property, plant and equipment 3,946 3,699
Capital-work-in-progress 4 0
Right-of-use assets 4,987 5,521
Goodwill 61,666 60,390
Other intangible assets 20,161 20,362
Trade receivables and Unbilled 14,224 12,668
Cash and cash equivalents 5,992 3,438
Deferred tax assets (net) 1,381 1,337
Other Assets 2,913 3,091
Total Assets 115,273 110,507
Equity 88,945 83,361
Borrowings 6,904 8,170
Lease liabilities 5,415 5,850
Trade payables 2,143 2,136
Deferred tax liabilities (net) 3,986 4,279
Other Liabilities 7,880 6,712
Total Liabilities 115,273 110,507
Amt in INR M

Cash Flow – H1 FY26
18
Particulars H1 FY26 FY25
Profit before tax for the period/ year 5,372 7,602
Adjustment for Non-Operating and Non-Cash items 2,362 6,982
Adjustment for working capital (309) (710)
Income taxes paid (net of refunds) (1,840) (1,734)
Net cash flows generated from operating activities (A) - OCF 5,585 12,141
Addition to Fixed Assets (810) (1,244)
Free Cash flow (FCF) 4,776 10,896
Cash paid for M&A 0 (4,825)
Pending Purchase consideration paid for healthcare business carveout 0 (3,756)
Investment in Mutual fund and Fixed Deposit (3,021) 0
Others 107 184
Net cash flows (used in) investing activities (B) (3,724) (9,642)
Capital infused by promoter 0 3,708
Share Issue expense (paid)/ reimbursed 0 72
Repayment of Promoter borrowings (include Interest) (1,559) (4,567)
Repayment of lease liabilities (include Interest) (911) (1,774)
Net cash flows (used in) financing activities (C) (2,471) (2,561)
Net increase/ (decrease) in cash and cash equivalents (A+B+C) (609) (62)
Cash and cash equivalents at the beginning of the year/period 3,438 3,441
Effect of movement in exchange rates on cash and cash equivalents 87 58
Cash and cash equivalents at the end of the year/ period 2,915 3,438
Net cash flows generated from operating activities % (OCF on Reported EBITDA) 67.3% 89.7%
Free Cash flow % (FCF on Reported EBITDA) 57.6% 80.5%
Amt in INR M

Thank You